 |
| Positive Phase II data on TRX4 (ChAglyCD3) |
13 May 2007 - BTG
BTG plc, the medical innovations company, notes that TolerRx, Inc., BTG’s licensee for the anti-CD3 technology, has announced publication of positive Phase II data on TRX4 (ChAglyCD3), showing that a six-day course of TRX4 therapy in patients with type 1 diabetes reduced the amount of insulin needed to control blood glucose levels for at least 18 months. |
|
|
| BTG licenses haemofiltration device patents to Fresenius Medical Care |
22 April 2007 - BTG
BTG plc, the medical innovations company, announces that it has granted Fresenius Medical Care AG & Co. KGaA a non-exclusive licence for the global rights to patents relating to a haemofiltration device for €4.5 million fully paid |
|
|
| New CP-141, a novel modified oral formulation of a product used for the treatment of asthma |
21 April 2007 - BTG
BTG, the medical innovations company, announced today that it has entered into a Collaboration Agreement with Collegium Pharmaceutical, Inc., a specialty product development company, to develop CP-141, a novel modified oral formulation of a product used for the treatment of asthma. |
|
|
| BTG licenses analgesic compounds from Asterand |
20 April 2007 - BTG
BTG plc, the medical innovations company, and Asterand plc (formerly Pharmagene plc) announce that the companies have entered into an exclusive licence agreement, whereby BTG acquires the rights to a series of compounds discovered and developed by Asterand to treat painful conditions such as migraine headache. |
|
|
| BTG completes sale of RFID patent portfolio |
19 April 2007 - BTG
BTG plc, the medical innovations company, today announces that Zebra Technologies Corporation has exercised its option to acquire the remainder of BTG's radio frequency identification patent portfolio for $3.8 million gross. |
|
|
| Strata Technology partners retained by BTG to auction rights to a substantial OLED patent portfolio |
18 April 2007 - BTG
Strata Technology Partners, the London-based corporate finance advisory firm, announced today that it has been retained by BTG plc to auction the control over a substantial OLED patent portfolio via an exclusive license with prosecution, sublicensing and litigation rights in the field of information displays. |
|
|
| Study met primary endpoint of progression free survival with Campath |
17 April 2007 - BTG
Genzyme Corporation and Berlex Inc., a U.S. affiliate of Schering AG, Germany, majority-owned by the Bayer Group, today announced results from CAM307, an international Phase III clinical trial comparing Campath (alemtuzumab) with chlorambucil in previously untreated patients with B-cell chronic lymphocytic leukemia. The study data were presented at the 48th Annual Meeting of the American Society of Hematology in Orlando. |
|
|
| Genzyme reports Phase III data showing Campath is superior to Chlorambucil as a first-line therapy in B-CLL |
16 April 2007 - BTG
BTG plc, the medical innovations company, notes that its licensee Genzyme Corporation has published positive results from a Phase III study comparing Campath with Chlorambucil in previously untreated patients with B-cell chronic lymphocytic leukaemia. An extract from the announcement follows. |
|
|
| European phase III randomised controlled trial comparing Varisolve with surgery or sclerotherapy |
15 April 2007 - BTG
BTG plc, the medical innovations company, announces that the full results of the Phase III European trial of Varisolve, the novel microfoam treatment for varicose veins, have been published in the journal Phlebology 1, confirming the non-inferiority of Varisolve to the alternative treatments. |
|
|
| BTG licensee TolerRx, Inc. raises $35.6m to develop TRX4; Phase III pivotal trial in type 1 diabetes |
03 November 2006 - BTG
BTG plc, the medical innovations company, today announces that TolerRx, Inc. has raised $35.6 million to advance the development of TRX4 as a treatment for type 1 diabetes and plans to commence a Phase III pivotal trial in 2006. TolerRx, BTG's exclusive licensee for the anti-CD3 monoclonal antibody TRX4, is also developing TRX4 as a treatment for psoriasis. |
|
|
| New scientific research shows low-level supplements of Potassium to normal diet can lower blood pressure |
03 November 2006 - BTG
Data published in July edition of British Journal of Nutrition from King’s College London suggests addition of potassium to consumer foods and beverages could provide significant health benefits. |
|
|
| New surgical sealant technology from BTG |
15 October 2006 - BTG
BTG, the global technology commercialisation company, announced today it will commercialise the rights to a new surgical sealant technology, which could replace traditional suturing in surgery, as well as provide advantages over biochemical sealants currently in use. |
|
|
| MCA approves pivotal Phase III trials for Varisolve in the UK |
15 October 2006 - BTG
BTG plc announced that its wholly owned subsidiary, Provensis Ltd, has received a letter of approval from the Medicines Controls Agency for its Clinical Trials Exemption confirming that the Phase III study for its Varisolve procedure can go ahead in the UK. |
|
|
| New drug to treat chronic lymphocytic leukaemia likely to go on sale by end of the year |
14 October 2006 - BTG
BTG, the global technology commercialisation company, announced today that the U.S. Food & Drug Administration has granted accelerated approval of Campath (alemtuzumab) humanised monoclonal antibody for use as a treatment for patients with B-cell chronic lymphocytic leukaemia who have been treated with alkylating agents and have failed fludarabine therapy. |
|
|
| New tamoxifen formulation shown to substantially retard growth of resistant tumors |
14 October 2006 - BTG
Scientists have discovered a new formulation of tamoxifen which can treat breast cancers that are resistant to the standard formulation of the drug. Tamoxifen is the most widely prescribed breast cancer medicine in the world. BTG, the global technology commercialisation company, is now working to develop and commercialise liposomal tamoxifen, this new drug. |
|
|
| BTG reports positive results from UK Varisolve trials |
13 October 2006 - BTG
BTG, the global technology commercialisation company, today announced that its wholly owned subsidiary, Provensis, reported findings from the independent physician-led trials of Varisolve, the new microfoam treatment for varicose veins. Two pilot studies were conducted in Aberdeen and Manchester and both demonstrated the treatment to be safe and effective. |
|
|
| BTG launches company to develop breakthrough technology to treat broad array of neurological conditions |
13 October 2006 - BTG
London, UK: BTG, the global technology commercialisation company, today launched KetoCytonyx, Inc., a company created to develop BTG’s ketone body technology. |
|
|
| BTG licences the electro-absorption modulator technology |
12 October 2006 - BTG
BTG, the global technology commercialisation company, today announced it has signed licensing agreements with Oki Electric Industry Co. Ltd., a telecommunications manufacturer, and NTT Electronics Corporation, a worldwide supplier of high performance opto-electronic products, for the Electro-Absorption Modulator technology. |
|
|
| BTG announces X-MatchPROVW licensing opportunity |
12 October 2006 - BTG
BTG, a global leader in commercialising technology, is seeking companies interested in licensing X-MatchPROVW, the next generation of the X-MatchPRO technologies originally commercialised by BTG. X-MatchPROVW is a fully verified, lossless compression technology that enables companies to realise significant savings in time and money, by quickly and easily doubling both the bandwidth of their data transmission lines and the capacity of their storage networks. |
|
|
| BTG initiates Phase I trial of AQ4N, an innovative cancer drug |
11 October 2006 - BTG
BTG, a global leader in commercialising innovative technologies, announced today the start of a Phase I clinical study to test AQ4N, a new drug designed to increase the effectiveness of several widely-used anticancer drugs as well as radiotherapy. |
|
|
| New technology with potential for real-time detection of anthrax and other infectious diseases |
11 October 2006 - BTG
BTG, the global technology commercialisation company, today announced it has acquired a new diagnostic technology that has the potential to offer real-time detection of infectious diseases, such as anthrax, smallpox, AIDS and influenza. The primary application for the fibre optic based sensor is in the point-of-care medical market, but it can also be incorporated into environmental monitoring systems to detect airborne diseases. |
|
|
| New drug application filed for BTG's Oxycodone HCl/Ibuprofen technology |
10 October 2006 - BTG
BTG, the global technology commercialisation company, announced today that Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, has submitted a New Drug Application with the U.S. |
|
|
| BTG acquires innovative compounds for use in treating cardiac and renal disease |
10 October 2006 - BTG
BTG, the global technology commercialisation company, has obtained exclusive rights from Genentech, Inc. to develop and commercialise an Atrial Natriuretic Factor peptide technology, shown to have therapeutic potential in treating acute congestive heart failure, acute renal failure and renal hypertension. BTG is seeking to license this technology. |
|
|
| BTG and ISREC release new data supporting use of Adenoviral Treatment for Colorectal Cancer |
09 October 2006 - BTG
BTG, the global technology commercialisation company, and the Swiss Institute for Experimental Cancer Research released data that supports the development of a new approach to treat colorectal cancer. As demonstrated in their in vitro studies published in the current issue of Gene Therapy, researchers exploited a genetic defect commonly found in colorectal cancer cells to engineer a virus that selectively replicates within and destroys these tumour cells. |
|
|
| Leading scientists join BTG network to explore potential of nanotechnology |
09 October 2006 - BTG
BTG, the global technology commercialisation company, today launched the BTG Nanotechnology Network, a think-tank of leading international scientists working in the fields of nanotechnology. |
|
|
| Leading scientists join BTG network to explore potential of nanotechnology |
09 October 2006 - BTG
BTG, the global technology commercialisation company, today launched the BTG Nanotechnology Network, a think-tank of leading international scientists working in the fields of nanotechnology. |
|
|
| Multicarrier power amplification technology projected to save GSM providers up to $30 million per network |
08 October 2006 - BTG
BTG, the global technology commercialisation company, today announced its acquisition of a new multi-branch feed-forward technology, from Simon Fraser University in Vancouver, Canada. Global Systems for Mobile Communications network operators, who are currently using single carrier power amplifiers, will now be able to take advantage of the benefits of using multicarrier power amplifiers. |
|
|
| Breakthrough products eliminate bandwidth & cost barriers enabling delivery of high quality video |
08 October 2006 - BTG
BTG, the global technology commercialisation company, today announced it will market a portfolio of MPEG-compatible video distribution products developed by Digital Interactive Streams, Inc. (DiStream) that will enable the delivery of near DVD quality digital video at 1 Mbps over existing telephone and cable networks with unprecedented security measures. |
|
|
| Collaboration to jointly develop to commercialise a light-emitting polymer technology for flexible displays |
08 October 2006 - BTG
BTG, the global technology commercialisation company, today announced a collaboration agreement with Taiwan's Union Chemical Laboratories of the Industrial Technology Research Institute to jointly develop and to commercialise a patented light-emitting polymer technology for flexible organic/polymer light-emitting diode information displays. |
|
|
| BTG collaborates with INO to develop photonic technology |
08 October 2006 - BTG
BTG, the global technology commercialisation company, today announced that it has signed a strategic alliance agreement with INO, Canada’s largest optics and photonics expertise centre, that will provide the opportunity to co-invest in the development of forward-looking uses for photonics. |
|
|
| Senexis to develop novel treatments for ageing-related diseases |
07 October 2006 - BTG
BTG plc, the global technology commercialisation company, today announced an investment in Senexis Limited, a new biotechnology company focusing on the development of pharmaceuticals for the diagnosis and treatment of ageing-related diseases caused by a common pathogenic process called amyloidosis. Senexis Limited has raised £1.4 million of start-up financing from BTG and Catalyst BioMedica Limited, and will be based at The University of Manchester Institute of Science and Technology. |
|
|
| BTG licenses new class ofpPsychiatric drugs to Abiogen Pharma S.p.A |
07 October 2006 - BTG
BTG, the global technology commercialisation company, today announced it has exclusively licensed to Abiogen Pharma S.p.A the worldwide intellectual property rights to two compounds with the potential to treat anxiety and depression. |
|
|
| BTG successfully defends key patent for GSM and 3G value added services |
07 October 2006 - BTG
BTG, the global technology commercialisation company, today announced the decision by the European Patent Office to uphold its patent relating to GSM, GPRS and 3G mobile communications. The Patent had been opposed by leading SIM Card manufacturers, following its grant in 1998. |
|
|
| PMS 601 provides novel approach to fighting HIV with potential to improve effects of other existing therapies |
07 October 2006 - BTG
BTG, the global technology commercialisation company, has acquired a new class of drug candidates, discovered in France, that are targeted to treat advanced and chronic HIV infection. |
|
|
| New approach to drug delivery through bioadhesive ophthalmic drug insert |
06 October 2006 - BTG
BTG, the global technology commercialisation company, today announced it had strengthened its portfolio of ophthalmic technologies with the acquisition of a new drug delivery innovation from the French veterinary pharmaceutical laboratory Vétoquinol. |
|
|
| Collaboration to Assist Intellectual Property Owners in Realising Hidden Value of Patents |
06 October 2006 - BTG
BTG plc, the global technology commercialisation company, today announced a collaboration with Semiconductor Insights, the leader in technical and patent analyses of integrated circuits and structures, to help semiconductor intellectual property owners maximise the return on their investments. |
|
|
| Technology developed at Cincinnati Children's and Licensed to BTG to significantly benefit adults |
06 October 2006 - BTG
Cincinnati Children’s Hospital Medical Centre and BTG, a global technology commercialisation company, have entered into a licensing and commercialisation agreement that will provide significant benefit to children and adults who are on dialysis due to kidney disorders. |
|
|
| BTG plc: Provensis receives FDA approval to commence pilot study with Varisolve |
06 October 2006 - BTG
BTG plc, the global technology commercialisation company, today announced that its subsidiary Provensis Ltd has gained approval from the Food & Drug Administration to commence the first stage of a pilot study in patients in the US with Varisolve, the non-invasive procedure being developed to treat varicose veins. |
|
|
| New gene technology shown to enable production of industrial oils from a wider range of oil-seed crops |
05 October 2006 - BTG
BTG , the global technology commercialisation company, today announced it will commercialise a new gene modification technology that uses a naturally-occurring plant gene to produce commercially valuable oils in soybean and other oil-seed crops. Developed at the University of British Columbia, the technology modifies the fatty acid composition of plants, which provides a higher percentage of oil suitable for industrial applications. |
|
|
| VARISOLVE shown similar in efficacy to, and with significant potential advantages over, existing treatments |
05 October 2006 - BTG
BTG plc, the global technology commercialisation company, today announced the preliminary results of a pivotal European Phase III trial of the VARISOLVE endovenous microfoam procedure, being developed by its subsidiary Provensis Ltd as a new treatment for varicose veins. |
|
|
| BTG signs agreement with Atmel to collaborate in design & manufacture of radio frequency |
05 October 2006 - BTG
BTG, the global technology commercialisation company, has announced that it has signed (in association with its RFID Venture Company, RFIP Solutions) a co-operation agreement for a UHF RFID ISO 18000-6 type chip with Atmel Corporation, a global leader in the design and manufacture of advanced logic, mixed-signal, non-volatile memory and RF semiconductors. The two companies will work together to bring added value to UHF RFID tags and systems. |
|
|
| Diagnostic technology featured in Clinical Chemistry uses serum from maternal whole blood |
05 October 2006 - BTG
BTG, the global technology commercialisation company, announced the issuance of U.S. Patent No. 6,258,540 covering its non-invasive method to evaluate foetal DNA in maternal blood samples. This technology has been demonstrated to accurately identify several inherited disorders, such as Down’s syndrome. BTG is actively seeking commercial partners to advance its development. |
|
|
| Biological compound could provide basis for broad-spectrum HIV treatment. |
04 October 2006 - BTG
BTG, the global technology commercialisation company, announced today that it has acquired an important new human HIV antibody technology from researchers at BioClonetics. The antibody, identified as Clone 3, represents only the fifth human antibody worldwide with known anti-HIV potential. It has been demonstrated in in vitro tests to neutralise several clinical/primary strains of HIV virus. |
|
|
| BTG & Cohen Marketing Services announce new way to add a Healthy Kick to snack foods & baked goods |
04 October 2006 - BTG
BTG, the global technology commercialisation company, and Cohen Marketing Services today announced an agreement allowing BTG to commercialise a technology that enables higher soy content in several food product categories, including baked goods, snack foods (chips, cookies), and any other dough-based speciality foods. |
|
|
| BTG licenses two-part hip cup patents to Wright Medical Technology, Inc. |
04 October 2006 - BTG
BTG, the global technology commercialisation company, today announced it has successfully licensed the two-part hip cup patents for a license fee and future royalty payments to Wright Medical Technology, Inc., a world wide designer, manufacturer and distributor of orthopaedic implants and instruments. |
|
|
| Venture Fund to link Boston-Toronto-Montreal in Life Sciences Partnership |
04 October 2006 - BTG
VIMAC Ventures LLC, RBC Technology Ventures Inc., and BTG are pleased to announce the commencement of VIMAC Milestone Medica Fund, an early stage life sciences fund. VMM is the latest in VIMAC Ventures’ Boston-based family of funds and has offices in Boston and Montreal. |
|
|
| Compounds to be developed for selected inflammatory diseases |
03 October 2006 - BTG
BTG, the global technology commercialisation company, announced today that it is seeking partners to develop and commercialise its PDE-4 inhibitor portfolio for specific inflammatory indications outside of respiratory disease. |
|
|
| UK Scientists make breakthrough in fight against Coeliac Disease |
03 October 2006 - BTG
BTG, the global technology commercialisation company, and Isis Innovation Ltd, the technology transfer company of the University of Oxford, announce their agreement for the commercialisation of a new coeliac disease technology developed by the University of Oxford. |
|
|
| Phase I/II trial to be initiated for drug with promising cancer fighting abilities |
03 October 2006 - BTG
BTG, the global technology commercialisation company, today announced plans for the further development of a potential treatment for gastrointestinal cancers such as gastric and pancreatic. The drug, BGC 9331, which is a non-polyglutamatable thymidylate synthase inhibitor, will be investigated in a phase I/II trial for its use as a first-line treatment for gastric cancer. |
|
|
| BTG licenses important new cancer drug to KuDOS Pharmaceuticals |
03 October 2006 - BTG
BTG the global technology commercialisation company today announced a licence agreement with Kudos Pharmaceuticals under which KuDOS has been granted worldwide, exclusive rights to the new cancer drug AQ4N. KuDOS will be responsible for the further development and commercialisation of the drug. BTG has received a signature fee and will be entitled to milestone and other payments, and ultimately a royalty on sales. |
|
|
| BTG invests in leading syndicate developing compounds with therapeutic potential in neurosciences |
02 October 2006 - BTG
BTG today announced it had invested in Avera Pharmaceuticals, Inc., a neuropharmaceutical licensing and development company, which recently completed a $16 million Series A venture capital financing led by Frazier Healthcare Ventures. Also included among the investors were Bay City Capital, InterWest Partners, Windamere Venture Partners, LLC, St. Paul Venture Capital and GlaxoSmithKline. |
|
|
| Iclectus to develop intrabody and masked antisense based drugs to treat cancer |
02 October 2006 - BTG
BTG, the global technology commercialisation company, today announced an investment in Iclectus Limited, a new biotechnology company that will focus on developing intrabody and masked antisense molecules as therapies for the treatment of cancer, and as tools for validating new drug targets produced, for example, by the sequencing of the human genome. |
|
|
| BioPharmaceutical models offer cheap, effective screening & metabolic assessment of compounds |
02 October 2006 - BTG
BTG, the global technology commercialisation company, today announced it has acquired exclusive rights to a range of computer-based Lewis P450 Models which are affordable, accurate and have predictive capabilities for the rapid screening and profiling of compounds. These models, available for license on a single-pay, non-exclusive basis, are already being used by a number of pharmaceutical companies and represent one element in a growing portfolio of drug development technologies being commercialised by BTG. |
|
|
| BTG and Gentronix Ltd to market novel Genotoxicity Testing System |
01 October 2006 - BTG
BTG, the global technology commercialisation company, announced today an exclusive three-year Marketing Agency Agreement with Gentronix Ltd (Manchester, UK). Gentronix, a spin off from the University of Manchester Institute of Science and Technology, was founded to develop and commercialise a genotoxicity testing platform devised by Dr Richard Walmsley (founder and Chief Scientific Officer of Gentronix). |
|
|
| BTG strengthens drug portfolio in diseases of ageing |
01 October 2006 - BTG
BTG, the intellectual property and technology commercialisation company, announced today that it has acquired two innovative drug discovery programmes from King’s College London. These acquisitions will strengthen BTG’s portfolio in the areas of diabetes and neurodegeneration, two major focus areas of BTG’s Ageing & Neuroscience Business Unit. |
|
|
| BTG and Collegium Pharmaceutical to develop a modified release Asthma product |
01 October 2006 - BTG
BTG, the medical innovations company, announced today that it has entered into a Collaboration Agreement with Collegium Pharmaceutical, Inc., a specialty product development company, to develop CP-141, a novel modified oral formulation of a product used for the treatment of asthma. |
|
|
| BTG seeks exclusive licensee for a technology on transparent cathodes in Polymer OLED Devices |
01 October 2006 - BTG
BTG, the intellectual property and technology commercialisation company, today announced its plan to seek an exclusive licensee for a fundamental technology that uses transparent cathodes in polymer organic light emitting diode devices. |
|
|
| BTG and Collegium Pharmaceutical to develop a modified release Asthma product |
01 October 2006 - BTG
BTG, the medical innovations company, announced today that it has entered into a Collaboration Agreement with Collegium Pharmaceutical, Inc., a specialty product development company, to develop CP-141, a novel modified oral formulation of a product used for the treatment of asthma. |
|
|
| BTG licenses Barnes & Noble to its online navigation tracking patents |
30 September 2006 - BTG
BTG announces it has reached a settlement with BarnesandNoble.com over a patent infringement lawsuit filed by BTG. The financial terms of the settlement with Barnes & Noble are undisclosed. As a result of this settlement, BTG has dismissed its claims and granted Barnes & Noble a non-exclusive license to patents covering technology for tracking the navigational path of a user through the World Wide Web. |
|
|
| BTG licenses the Electro-Absorption Modulator & Distributed FeedBack Laser Technologies to Mitsubishi Electric |
30 September 2006 - BTG
BTG, the intellectual property and technology commercialisation company, today announced that it has signed a licence agreement with Mitsubishi Electric Corporation for the Electro-Absorption Modulator and the Distributed Feedback laser technologies. Both of these technologies, used to produce high quality modulated optical signals at data rates of 1.0 Gbit/s and above, play an integral role in making more efficient use of long distance optical telecommunications networks. |
|
|
| BTG licenses Barnes & Noble to its online navigation tracking patents |
30 September 2006 - BTG
BTG announces it has reached a settlement with BarnesandNoble.com over a patent infringement lawsuit filed by BTG. The financial terms of the settlement with Barnes & Noble are undisclosed. As a result of this settlement, BTG has dismissed its claims and granted Barnes & Noble a non-exclusive license to patents covering technology for tracking the navigational path of a user through the World Wide Web. |
|
|
| X-ray crystallography structure of human cytochrome 2C9 shows good agreement with Lewis P450 Model |
30 September 2006 - BTG
BTG, the intellectual property and technology commercialisation company, today highlighted the reference in April’s edition of Pharmacogenomics of the remarkable three-dimensional alignment of the structure of the human cytochrome P450, CYP2C9, depicted in Professor Lewis’ 3-D Model, compared to the X-ray crystal structure solved by P.A. Williams et al. The Lewis P450 Models, including those of CYP2C9, are being commercialised exclusively by BTG. |
|
|
| BTG announces licensing agreement with Gambro Renal |
30 September 2006 - BTG
BTG, the global technology commercialisation company, announced today that it has successfully licensed patents surrounding a hemofiltration device developed at Cincinnati Children’s Hospital Medical Center to international dialysis product manufacturer Gambro Renal Products. The agreement involved a down payment and provides for ongoing royalties. BTG acquired the rights to commercialise this intellectual property from Cincinnati Children’s Hospital. |
|
|
| Collaboration with Irish BioVentures to assist BTG in finding, developing and commercialising technologies |
29 September 2006 - BTG
BTG, the global technology commercialisation company, today announced a strategic alliance with Irish BioVentures International Ltd, Ireland’s premier source of venture development services for the life sciences and healthcare industries. |
|
|
| BTG strengthens non-invasive prenatal diagnostic technology patent portfolio |
29 September 2006 - BTG
BTG, the intellectual property and technology commercialisation company, announced today that it has strengthened its non-invasive prenatal diagnosis patent portfolio through the acquisition of a novel cellular foetal DNA diagnostic. |
|
|
| KetoCytonyx reports positive Phase I study of neuroprotectant |
29 September 2006 - BTG
Ketocytonyx, Inc., a pharmaceutical development company focused on cell protection therapeutics, today announced the successful completion of a Phase I clinical study of KTX 0101, its lead therapeutic targeting prevention of cognitive impairment in patients undergoing coronary artery bypass graft surgery. |
|
|
| Innovative pharmacological approach for the treatment of sleep-related breathing disorders |
29 September 2006 - BTG
BTG, the medical innovations company, announced today that it has initiated patient enrolment for a proof of mechanism clinical trial for BGC20-0166, its novel pharmacologic therapy for the treatment of obstructive sleep apnoea. BGC20-0166 targets two distinct mechanisms of serotonin signaling. |
|
|
| KetoCytonyx reports positive Phase I study of neuroprotectant |
29 September 2006 - BTG
Ketocytonyx, Inc., a pharmaceutical development company focused on cell protection therapeutics, today announced the successful completion of a Phase I clinical study of KTX 0101, its lead therapeutic targeting prevention of cognitive impairment in patients undergoing coronary artery bypass graft surgery. |
|
|
| BTG strengthens non-invasive prenatal diagnostic technology patent portfolio |
29 September 2006 - BTG
BTG, the intellectual property and technology commercialisation company, announced today that it has strengthened its non-invasive prenatal diagnosis patent portfolio through the acquisition of a novel cellular foetal DNA diagnostic. The technology, developed by Professor Maj Hulten, has the ability to identify foetal DNA from the mixed cell population in the maternal bloodstream. This will allow foetal chromosomes to be investigated for several chromosome disorders, including Trisomy 21 (underlying cause of Downs syndrome) from a maternal blood sample, without contamination by maternal chromosomes. |
|
|
| Collaboration with Irish BioVentures to assist BTG in finding, developing and commercialising technologies in Ireland |
29 September 2006 - BTG
BTG, the global technology commercialisation company, today announced a strategic alliance with Irish BioVentures International Ltd, Ireland’s premier source of venture development services for the life sciences and healthcare industries. IBV will work with BTG to source and review Intellectual Property assets and venture opportunities within the life sciences. This agreement enables BTG to expand its sourcing activities in both the Republic of Ireland and Northern Ireland. |
|
|
| Innovative pharmacological approach for the treatment of sleep-related breathing disorders |
29 September 2006 - BTG
BTG, the medical innovations company, announced today that it has initiated patient enrolment for a proof of mechanism clinical trial for BGC20-0166, its novel pharmacologic therapy for the treatment of obstructive sleep apnoea. BGC20-0166 targets two distinct mechanisms of serotonin signaling. As the lead programme in BTG's drug repositioning portfolio, which currently consists of five development programmes involving new therapeutic uses or enhanced formulation of approved drugs, BTG has advanced BGC20-0166 from preclinical validation studies to the current clinical trial in less than eighteen months. The goals of the current clinical study are to investigate the efficacy of BGC20-0166 and to establish mechanistic proof of concept. |
|
|
| Lead compound has potential to improve the treatment of migraine |
28 September 2006 - BTG
BTG plc, the medical innovations company, and Asterand plc (formerly Pharmagene plc) announce that the companies have entered into an exclusive licence agreement, whereby BTG acquires the rights to a series of compounds discovered and developed by Asterand to treat painful conditions such as migraine headache. |
|
|
| BTG takes licence to new class of cancer drug from Cancer Research Technology and The Institute of Cancer Research |
28 September 2006 - BTG
BTG, the intellectual property and technology commercialisation company, announced that it has concluded a licence and research collaboration agreement with Cancer Research Technology Limited, the technology transfer company of the charity Cancer Research UK, and The Institute of Cancer Research, for a new class of cancer drug. |
|
|
| BTG and DxS sign exclusive licence with AstraZeneca to commercialise ARMS DNA diagnostic technology |
28 September 2006 - BTG
DxS and BTG announced today that they have signed an exclusive licence with AstraZeneca to commercialise the company’s proprietary Amplification Refractory Mutation System DNA diagnostic technology. ARMS is a simple, reliable and widely used method for the detection of gene mutations and single nucleotide polymorphisms. |
|
|
| Short-term administration with novel drug candidate significantly reduces insulin need in newly diagnosed Type 1 Diabetics |
28 September 2006 - BTG
A study published in the New England Journal of Medicine demonstrates that in patients with type 1 diabetes, a six day course of therapy with TRX4 (ChAglyCD3) preserves the function of insulin-producing beta cells in the pancreas and reduces the amount of administered insulin needed to control blood glucose levels for at least 18 months. |
|
|
| Lead compound has potential to improve the treatment of migraine |
28 September 2006 - BTG
BTG plc, the medical innovations company, and Asterand plc (formerly Pharmagene plc) announce that the companies have entered into an exclusive licence agreement, whereby BTG acquires the rights to a series of compounds discovered and developed by Asterand to treat painful conditions such as migraine headache. |
|
|
| Short-term administration with novel drug candidate significantly reduces insulin |
28 September 2006 - BTG
A study published in the New England Journal of Medicine demonstrates that in patients with type 1 diabetes, a six day course of therapy with TRX4 (ChAglyCD3) preserves the function of insulin-producing beta cells in the pancreas and reduces the amount of administered insulin needed to control blood glucose levels for at least 18 months. |
|
|
| BTG takes exclusive licence to new class of cancer drug from Cancer Research Technology |
28 September 2006 - BTG
BTG, the intellectual property and technology commercialisation company, announced that it has concluded a licence and research collaboration agreement with Cancer Research Technology Limited, the technology transfer company of the charity Cancer Research UK, and The Institute of Cancer Research, for a new class of cancer drug. |
|
|
| BTG and DxS sign exclusive licence with AstraZeneca to commercialise ARMS DNA diagnostic technology |
28 September 2006 - BTG
DxS and BTG announced today that they have signed an exclusive licence with AstraZeneca to commercialise the company’s proprietary Amplification Refractory Mutation System DNA diagnostic technology. ARMS is a simple, reliable and widely used method for the detection of gene mutations and single nucleotide polymorphisms. |
|
|
| Announcement highlights corporate trend towards IP asset licensing |
27 September 2006 - BTG
BTG, a global technology commercialisation company, and Corning Incorporated, a diversified technology company, announced today that they have signed a representation agreement whereby BTG will seek licensees on behalf of Corning for a portfolio of Corning patents related to a widely-used glass moulding process. |
|
|
| KetoCytonyx commences Phase I Study for Neuroprotectant KTX 0101 |
27 September 2006 - BTG
KetoCytonyx, Inc, a pharmaceutical development company focused on cell protection therapeutics, today announced that a Phase I clinical study has begun on KTX 0101, its lead therapeutic with a target indication of prevention of cognitive impairment in patients undergoing Coronary Artery Bypass Graft surgery. |
|
|
| BTG plc: Publication of positive data from TRX4 type 1 diabetes study |
27 September 2006 - BTG
BTG plc, the medical innovations company, notes that TolerRx, Inc., BTG’s licensee for the anti-CD3 technology, has announced publication of positive Phase II data on TRX4 (ChAglyCD3), showing that a six-day course of TRX4 therapy in patients with type 1 diabetes reduced the amount of insulin needed to control blood glucose levels for at least 18 months. |
|
|
| BTG to commence US phase II clinical safety study of Varisolve |
27 September 2006 - BTG
BTG plc, the medical innovations company, today announces that it intends to complete preparations for and commence a US phase II clinical safety study of Varisolve, the novel injectable microfoam treatment for varicose veins. |
|
|
| BTG plc: Publication of positive data from TRX4 type 1 diabetes study |
27 September 2006 - BTG
BTG plc, the medical innovations company, notes that TolerRx, Inc., BTG’s licensee for the anti-CD3 technology, has announced publication of positive Phase II data on TRX4 (ChAglyCD3), showing that a six-day course of TRX4 therapy in patients with type 1 diabetes reduced the amount of insulin needed to control blood glucose levels for at least 18 months. |
|
|
| Announcement highlights corporate trend towards IP asset licensing |
27 September 2006 - BTG
BTG, a global technology commercialisation company, and Corning Incorporated, a diversified technology company, announced today that they have signed a representation agreement whereby BTG will seek licensees on behalf of Corning for a portfolio of Corning patents related to a widely-used glass moulding process. |
|
|
| KetoCytonyx commences Phase I Study for Neuroprotectant KTX 0101 |
27 September 2006 - BTG
KetoCytonyx, Inc, a pharmaceutical development company focused on cell protection therapeutics, today announced that a Phase I clinical study has begun on KTX 0101, its lead therapeutic with a target indication of prevention of cognitive impairment in patients undergoing Coronary Artery Bypass Graft surgery. |
|
|
| BTG to commence US phase II clinical safety study of Varisolve |
27 September 2006 - BTG
BTG plc, the medical innovations company, today announces that it intends to complete preparations for and commence a US phase II clinical safety study of Varisolve, the novel injectable microfoam treatment for varicose veins. |
|
|
| BTG licenses new prostate cancer drug to Cougar Biotechnology |
26 September 2006 - BTG
BTG, the global technology commercialisation company and Los Angeles-based Cougar Biotechnology today announced that they have signed a licence agreement in which Cougar is granted worldwide exclusive rights to develop and commercialise abiraterone acetate, a potential novel therapeutic for treatment of advanced prostate cancer. BTG will receive an upfront cash payment and will benefit from further development milestones and a royalty on sales. Detailed financial terms were not disclosed. |
|
|
| BTG plc: Varisolve given FDA approval to recommence US clinical trials |
26 September 2006 - BTG
BTG plc, the medical innovations company, today announces that its subsidiary Provensis has received approval from the US Food and Drug Administration to resume clinical development of Varisolve, which is being developed as a novel microfoam treatment for varicose veins. |
|
|
| Innovative pharmacological approach for the treatment of sleep-related disorder |
26 September 2006 - BTG
BTG, the intellectual property and technology commercialisation company, today announced that it has signed a licensing and research agreement with the University of Illinois at Chicago to further develop a novel pharmacological therapy for the treatment of sleep apnoea. BTG plans to invest in the development of this innovative therapy to expand its portfolio of therapeutic programmes, particularly in the area of drug repositioning. Under the terms of the agreement, UIC grants BTG specific exclusive rights to intellectual property and inventions related to the development of therapeutic treatment of sleep apnoea, as well as rights to new intellectual property developed through the BTG-funded research programme. |
|
|
| TolerRx, Inc. Advance TRX4 in Type 1 Diabetes - Adds seven new investors including FrontPoint Partners |
26 September 2006 - BTG
TolerRx, Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat patients with diseases of the immune system, announced that it has completed a $35.6 million financing, which included funding from the Juvenile Diabetes Research Foundation, the world's largest charitable sponsor of research in Type 1 diabetes. The funds will support the clinical development of TolerRx's lead product, TRX4, an anti-CD3 monoclonal antibody in development for Type 1 diabetes and psoriasis. TolerRx is currently conducting clinical trials of TRX4 in subjects with Type 1 diabetes and plans to initiate a Phase III pivotal trial. |
|
|
| TolerRx, Inc. Advance TRX4 in Type 1 Diabetes, Adds seven new investors including FrontPoint Partners |
26 September 2006 - BTG
TolerRx, Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat patients with diseases of the immune system, announced that it has completed a $35.6 million financing, which included funding from the Juvenile Diabetes Research Foundation, the world's largest charitable sponsor of research in Type 1 diabetes. |
|
|
| BTG plc: Varisolve given FDA approval to recommence US clinical trials |
26 September 2006 - BTG
BTG plc, the medical innovations company, today announces that its subsidiary Provensis has received approval from the US Food and Drug Administration to resume clinical development of Varisolve, which is being developed as a novel microfoam treatment for varicose veins. |
|
|
| Innovative pharmacological approach for the treatment of sleep-related disorder |
26 September 2006 - BTG
BTG, the intellectual property and technology commercialisation company, today announced that it has signed a licensing and research agreement with the University of Illinois at Chicago to further develop a novel pharmacological therapy for the treatment of sleep apnoea. |
|
|
| BTG licenses new prostate cancer drug to Cougar Biotechnology |
26 September 2006 - BTG
BTG, the global technology commercialisation company and Los Angeles-based Cougar Biotechnology today announced that they have signed a licence agreement in which Cougar is granted worldwide exclusive rights to develop and commercialise abiraterone acetate, a potential novel therapeutic for treatment of advanced prostate cancer. |
|
|
| BTG announces availability of a Novel Chalcogenide Laser for License |
25 September 2006 - BTG
BTG, the IP and technology commercialisation company, today announced that it is offering for license patented, fundamental chalcogenide semiconductor laser technology, which can provide broad functionality for sensing and laser ablation applications. |
|
|
| BTG establishes collaboration agreement with Collegium Pharmaceutical |
25 September 2006 - BTG
BTG, the intellectual property and technology commercialisation company, announced today that it has entered into a Collaboration Agreement with Collegium Pharmaceutical, Inc., to develop novel formulations of its combination drug therapy currently being developed for the treatment of sleep apnoea. |
|
|
| BTG licensee TolerRx, Inc. raises $35.6m to develop TRX4; Phase III pivotal trial in type 1 diabetes |
25 September 2006 - BTG
BTG plc, the medical innovations company, today announces that TolerRx, Inc. has raised $35.6 million to advance the development of TRX4 as a treatment for type 1 diabetes and plans to commence a Phase III pivotal trial in 2006. TolerRx, BTG's exclusive licensee for the anti-CD3 monoclonal antibody TRX4, is also developing TRX4 as a treatment for psoriasis. |
|
|
| BTG licenses fundamental online navigation tracking patents to Netflix |
25 September 2006 - BTG
BTG plc announced it has reached a full and final settlement with Netflix Inc. in connection with a patent infringement lawsuit filed by BTG in September 2004 against Netflix and other organisations. As a result of this settlement, BTG has dismissed its claims against Netflix and granted Netflix a non-exclusive licence to patents covering technology for tracking the navigational path of a user through the World Wide Web. |
|
|
| BTG licenses fundamental online navigation tracking patents to Netflix |
25 September 2006 - BTG
BTG plc announced it has reached a full and final settlement with Netflix Inc. in connection with a patent infringement lawsuit filed by BTG in September 2004 against Netflix and other organisations. As a result of this settlement, BTG has dismissed its claims against Netflix and granted Netflix a non-exclusive licence to patents covering technology for tracking the navigational path of a user through the World Wide Web. The suit against the other parties, Amazon.com, BarnesandNoble.com and Overstock.com, continues to be pursued. The financial terms of the settlement with Netflix are undisclosed. |
|
|
| BTG announces availability of a Novel Chalcogenide Laser for License |
25 September 2006 - BTG
BTG, the IP and technology commercialisation company, today announced that it is offering for license patented, fundamental chalcogenide semiconductor laser technology, which can provide broad functionality for sensing and laser ablation applications. The technology package, originally developed at the Lawrence Livermore National Laboratory, provides a versatile, tuneable, and more economical alternative to products already available on the market. A commercial prototype is currently under development at Canada’s INO and will be available to demonstrate this technology. |
|
|
| BTG establishes collaboration agreement with Collegium Pharmaceutical to develop innovative therapy for sleep apnoea |
25 September 2006 - BTG
BTG, the intellectual property and technology commercialisation company, announced today that it has entered into a Collaboration Agreement with Collegium Pharmaceutical, Inc., to develop novel formulations of its combination drug therapy currently being developed for the treatment of sleep apnoea. Collegium will employ its expertise in product development, including its suite of proprietary formulation technologies, with the goal of establishing a broadly patented single product with optimal properties for the treatment of this sleep-related breathing disorder. The Collaboration Agreement provides for a development programme that will be funded by BTG, as well as a revenue sharing arrangement between the parties. The intent of this Collaboration Agreement is for the sleep apnoea project to be the first of additional co-development programmes between the companies. |
|
|
| BTG seeks exclusive licensee for a fundamental technology on transparent cathodes in polymer OLED devices |
08 November 2004 - BTG
BTG, the intellectual property and technology commercialisation company, has announced its plan to seek an exclusive licensee for a fundamental technology that uses transparent cathodes in polymer organic light emitting diode (OLED) devices. |
|
|
| BTG grants Newlife Technologies Inc. a licence to an innovative medical monitoring technology |
15 April 2003 - BTG
BTG, a global technology commercialisation company, announced today that it has granted a licence to Newlife Technologies Inc. (Midlothian, VA) for an innovative non-invasive medical sensor technology. |
|
|
| BTG & The Generics Group combine key patents & grant licence for development of new bio-chip technology |
29 January 2003 - BTG
BTG, the global technology commercialisation company, announced today that it has worked with The Generics Group, the technology consulting, development and investment organisation, to create the potential for a new bio-chip technology. Together they are licensing a patent portfolio in electronics and the life sciences to Aura Oncology Systems Inc., which could lead to a bio-chip technology that could assist in the diagnosis of cancer and the development of new oncology drugs. |
|
|
| The U.S. FDA Oncologic Advisory Committee recommends new treatment, Campath |
28 October 2002 - BTG
BTG plc announces that the Oncologic Drug Advisory Committee to the U.S. Food & Drug Administration voted yesterday 14 to 1 to recommend accelerated approval of CAMPATH. |
|
|
| MRI and Quadrupole Resonance technologies from BTG available for license on PATEX |
12 September 2002 - BTG
CorporateIntelligence.com today announced the addition of high profile patent portfolios to its collection of more than 5,000 properties now available for license at www.patex.com. Added to the PATEX exchange are magnetic resonance imaging and Direct Quadrupole Resonance portfolios provided by BTG International, a leading technology commercialization company. |
|
|
| Innovative natural biopesticide to be developed |
15 May 2002 - BTG
A new sustainable crop that could provide the answer to one of the world's biggest pest problems has been developed as a result of a unique collaboration with Costa Rica. BTG, a global leader in commercialising technology, announced today that it has signed agreements to speed development of an innovative, naturally-derived compound that protects crops from nematode worms. The compound, known as DMDP, is found naturally in the Costa Rican tree, Lonchocarpus felipei, and offers major benefits over existing control methods. |
|
|
| BTG to commercialise innovative locking device |
15 February 2002 - BTG
BTG, a global leader in commercialising technology, announced today the acquisition of a technology which could significantly improve the securing of medical devices such as intravenous lines and catheters, using a unique line lock. |
|
|
| New way to naturally enrich cow's milk for improved nutrition |
02 December 2001 - BTG
BTG International announced today that it has signed a commercialisation agreement with the University of Guelph to market the rights to a novel technology for naturally enriching cow's milk with an omega-3 fatty acid known as docosahexaenoic acid or DHA. This nutrient is an essential part of a healthy diet for people of all ages but is particularly important during the early stages of a child's development. |
|
|
| BTG signs agreement with Avigen to develop Factor IX gene therapy for Haemophilia B |
18 June 2001 - BTG
BTG plc, the global technology commercialisation company, announced today that it has signed a licence agreement with Avigen Inc., a US-based gene therapy company. The agreement covers the use of the gene for Factor IX, an important blood protein, in Avigen's proprietary gene therapy delivery system which it is developing for the treatment of Haemophilia B. |
|
|
| BTG to license innovative 'light-switchable' technology developed by Smith & Nephew |
24 April 2001 - BTG
BTG International, a world leader in technology transfer, has signed an agreement with Smith & Nephew, the global medical device company, to commercialise certain applications of Smith & Nephew's innovative light switchable adhesive technology. |
|
|
| Conductus licenses high temperature superconductor patents from Lucent Technologies |
04 January 2001 - BTG
BTG announced today that Conductus Inc. has signed a license agreement for yttrium-barium-copper oxide patents and patent applications in Lucent Technologies' portfolio that are fundamental to the high temperature superconductor industry. BTG acted as Lucent's commercial advisor and licensing representative in this transaction and will receive a share of the fees and royalties paid to Lucent. |
|
|
| BTG sign licence agreement for grain stripper with major South American company |
12 November 2000 - BTG
BTG has signed a third licence agreement for its grain stripper with Carlos Mainero & Cia of Argentina. Under this agreement Mainero has the right to manufacture the stripper header in Argentina and sell products throughout South America. Mainero will also have the right to pursue potential infringers in this region. Other licensees for BTG's successful stripper header are Shelbourne Reynolds Engineering in the UK and AGCO in the US. |
|
|
| BTG acquires novel technology for the treatment of cytokine mediated disorders |
05 August 2000 - BTG
BTG plc has acquired, for licensing, a novel gene therapy approach for the treatment of numerous disorders that are known to be associated with excess production of specific cytokines. These disorders include asthma, allergic symptoms, septic shock syndrome and rheumatoid arthritis. This technology was developed by Dr Richard Zheng of Queen Mary and Westfield College, UK and Dr Peter Eagles of King's College London, UK. |
|
|
| Napier University researchers discover ground-breaking cancer treatments |
15 May 2000 - BTG
A research group led by an Edinburgh scientist has discovered potential new treatments for certain types of cancer both significantly more effective than current chemotherapeutic treatments and with fewer side effects. |
|
|
| BTG and Cisco sign agreement for key speech coding patents |
12 March 2000 - BTG
BTG plc announced that an agreement has been signed with Cisco Systems Inc. for two key patents relating to speech coding technology, which provide building blocks for transmitting real time speech over the internet, enabling improved internet telephony and video conferencing. |
|
|
| New market launch of Factor IX treatment for Haemophilia B |
20 January 2000 - BTG
BeneFIX, the first recombinant Factor IX therapy for the treatment of haemophilia B, has been launched in the UK and the majority of Europe by Baxter Hyland Immuno. BeneFIX was developed by BTG's licensee Genetics Institute, a wholly owned subsidiary of American Home Products Corporation. Baxter Healthcare has acquired exclusive distribution rights from GI for BeneFIX in Europe. |
|
